Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (71-80 of 344) with videos related to

Pageof 35
Sort By:
BMC Cancer|November 17, 2020
Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancerMashiro Okunaka, Daisuke Kotani, Ken Demachi, et al.
Annals of Gastroenterological Surgery|November 6, 2023
Neoadjuvant chemotherapy for locally advanced gastric cancer in Japan: Consensus meeting at the 77th general meeting of the Japanese Society of Gastroenterological SurgeryMasanori Tokunaga, Yukinori Kurokawa, Takeo Fukagawa, et al.
World Journal of Clinical Cases|December 3, 2020
Erratum: Author's Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (<i>World J Clin Cases</i> 2019; Aug 6; 7 (15): 1964-1977)Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, et al.
World Journal of Clinical Cases|August 20, 2019
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancerAkio Kaito, Takeshi Kuwata, Masanori Tokunaga, et al.
Investigational New Drugs|February 26, 2011
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trialsKohei Shitara, Junko Ikeda, Tomoya Yokota, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 16, 2011
Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancerKohei Shitara, Junko Ikeda, Chihiro Kondo, et al.
Expert Opinion on Biological Therapy|March 24, 2021
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyondJose Perez, Laia Garrigós, Maria Gion, et al.
Japanese Journal of Clinical Oncology|December 13, 2019
A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)Konosuke Moritani, Yukihide Kanemitsu, Dai Shida, et al.
International Heart Journal|May 14, 2025
A Fatal Case of Immune Checkpoint Inhibitor-Associated Myocarditis with Severe Right Ventricular FailureTakuro Imaoka, Kimi Sato, Shingo Sakashita, et al.
Japanese Journal of Clinical Oncology|August 7, 2007
Hepatic arterial infusion of oxaliplatin for a patient with hepatic metastases from colon cancer undergoing hemodialysisKohei Shitara, Masaki Munakata, Osamu Muto, et al.
Pageof 35

Showing results (71-80 of 344) with videos related to

Sort By:
Pageof 35
BMC Cancer|November 17, 2020
Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancerMashiro Okunaka, Daisuke Kotani, Ken Demachi, et al.
Annals of Gastroenterological Surgery|November 6, 2023
Neoadjuvant chemotherapy for locally advanced gastric cancer in Japan: Consensus meeting at the 77th general meeting of the Japanese Society of Gastroenterological SurgeryMasanori Tokunaga, Yukinori Kurokawa, Takeo Fukagawa, et al.
World Journal of Clinical Cases|December 3, 2020
Erratum: Author's Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (<i>World J Clin Cases</i> 2019; Aug 6; 7 (15): 1964-1977)Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, et al.
World Journal of Clinical Cases|August 20, 2019
HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancerAkio Kaito, Takeshi Kuwata, Masanori Tokunaga, et al.
Investigational New Drugs|February 26, 2011
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trialsKohei Shitara, Junko Ikeda, Tomoya Yokota, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|August 16, 2011
Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancerKohei Shitara, Junko Ikeda, Chihiro Kondo, et al.
Expert Opinion on Biological Therapy|March 24, 2021
Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyondJose Perez, Laia Garrigós, Maria Gion, et al.
Japanese Journal of Clinical Oncology|December 13, 2019
A randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)Konosuke Moritani, Yukihide Kanemitsu, Dai Shida, et al.
International Heart Journal|May 14, 2025
A Fatal Case of Immune Checkpoint Inhibitor-Associated Myocarditis with Severe Right Ventricular FailureTakuro Imaoka, Kimi Sato, Shingo Sakashita, et al.
Japanese Journal of Clinical Oncology|August 7, 2007
Hepatic arterial infusion of oxaliplatin for a patient with hepatic metastases from colon cancer undergoing hemodialysisKohei Shitara, Masaki Munakata, Osamu Muto, et al.
Pageof 35